3 ms·

I agree, the discussion here is reassuring. This may just be a case of a fraudulent paper piggybacking on an otherwise credible research program focusing on amy

I agree, the discussion here is reassuring. This may just be a case of a fraudulent paper piggybacking on an otherwise credible research program focusing on amyloid oligomers - not the plaques which recent failed therapies have targeted, and which many of these researchers knew were poor targets for decades before the FDA debacle over aducanumab. We can blame regulatory capture of the FDA for approval of failed drugs, rather than the scientific establishment. And we can blame Sylvain Lesné for Sylvain Lesné's fraud. I would encourage those of us whose only knowledge of this topic is the word "amyloid" (I admit I am one of them) to read the scientists' comments and appreciate that there is more to this than we know. There are complexities, nuances, diverse perspectives and healthy disagreements. It's not just a political battlefield. Projecting culture war into it would be harmful to the scientific progress we all value and to the millions who suffer from Alzheimer's.

koheripbal 4y ago
Their comments are not without self-interest. They all see the potential of their own funding being re-evaluated if they admit that any of their ongoing research build's on (or even references) Sylvain Lesné's work. They have an interest in limiting the scope of the perception of fraud in the field.
- civilized 4y ago
  And the people who want a change in direction have an interest in calling out any of that sort of thing that may be happening. So if it is, I hope to see it called out in a scientifically substantial way.